Treatment of Limited-Stage, Non-Bulky Angioimmunoblastic T-cell Lymphoma with a Favourable Pretherapeutic Risk Profile
This protocol addresses a distinct, well-characterised subset of angioimmunoblastic T-cell lymphoma: patients presenting with limited-stage, non-bulky disease and a favourable pretherapeutic risk profile — a group in which the initial therapeutic approach differs meaningfully from advanced-stage disease.
Clinical Scenario
Limited-stage, non-bulky angioimmunoblastic T-cell lymphoma with a favourable pretherapeutic risk profile. In this setting, the extent of initial chemotherapy may be modulated, and evidence supports considering an abbreviated treatment course rather than standard extended therapy.
Treatment Approach
An abbreviated chemotherapy course is among the approaches considered in this specific scenario. The full protocol specifies regimen options, cycle counts, eligibility criteria, and the complete management algorithm — including guidance for relapsed or refractory disease.
References
DOI: 10.1016/j.annonc.2025.01.023
- In patients with limited-stage, non-bulky disease and a favourable pretherapeutic risk profile, an abbreviated course of ChT (e.g. three to four cycles of CHOP or CHOEP) can be considered [IV, B].
- If a clinical trial is not available, platinum-based regimens that are non-cross resistant to the first-line anthracycline-based ChT can be considered [III, B].